Establishes a grant program to fund drug development trials for ibogaine to treat opioid use disorder and other conditions.

The bill establishes a grant program to fund drug development trials for ibogaine, a potential treatment for opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions. The Secretary of Health will administer the program, which includes issuing a notice of funding opportunity, selecting applicants, and establishing drug development trial sites. Applicants must submit an investigational new drug application to the FDA and seek a breakthrough therapy designation.

Establishes a grant program to fund drug development trials for ibogaine to treat opioid use disorder and other conditions.

The bill establishes a grant program to fund drug development trials for ibogaine, a potential treatment for opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions. The Secretary of Health will administer the program, which includes issuing a notice of funding opportunity, selecting applicants, and establishing drug development trial sites. Applicants must submit an investigational new drug application to the FDA and seek a breakthrough therapy designation.